S
Susan H. Fox
Researcher at University of Toronto
Publications - 220
Citations - 17609
Susan H. Fox is an academic researcher from University of Toronto. The author has contributed to research in topics: Dyskinesia & Parkinson's disease. The author has an hindex of 56, co-authored 208 publications receiving 14500 citations. Previous affiliations of Susan H. Fox include University of Manchester & University Health Network.
Papers
More filters
Journal ArticleDOI
Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease.
Joanne E. Nash,Susan H. Fox,Brian Henry,Michael Hill,David Peggs,Steve McGuire,Yannick P. Maneuf,C. J. Hille,Jonathan M. Brotchie,Alan R. Crossman +9 more
TL;DR: The data support the proposal that NR2B-selective NMDA receptor antagonists have potential as a nondopaminergic monotherapy for the treatment of parkinsonian symptoms when given de novo.
Journal ArticleDOI
Non-dopaminergic treatments in development for Parkinson's disease
TL;DR: Novel non-dopaminergic approaches that are in at least phase II clinical development for the treatment of Parkinson's disease are reviewed.
Journal ArticleDOI
Palliative care for advanced Parkinson disease: An interdisciplinary clinic and new scale, the ESAS-PD
Janis M. Miyasaki,J. Long,Deborah A Mancini,Elena Moro,Susan H. Fox,Anthony E. Lang,Connie Marras,Robert Chen,Antonio P. Strafella,R. Arshinoff,R. Ghoche,J. Hui +11 more
TL;DR: ESAS-PD is a quick, effective scale for assessment of late stage Parkinson disease symptoms that is sensitive to intervention, and therefore have potential clinical utility for physicians and other healthcare providers.
Journal ArticleDOI
Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: Keys to success and roads to failure
TL;DR: It is found that the major determinant of success in predicting efficacy is to ensure that primate studies are conducted in a statistically rigorous way and incorporate designs and outcome measures with clinical applicability, and phase IIa trials should strive to replicate the preclinical study so as to test the same hypothesis.
Journal ArticleDOI
Mutation analysis of CHCHD10 in different neurodegenerative diseases
Ming Zhang,Zhengrui Xi,Lorne Zinman,Amalia C. Bruni,Raffaele Maletta,Sabrina A.M. Curcio,Innocenzo Rainero,Elisa Rubino,Lorenzo Pinessi,Benedetta Nacmias,Sandro Sorbi,Daniela Galimberti,Anthony E. Lang,Anthony E. Lang,Susan H. Fox,Susan H. Fox,Ezequiel Surace,Mahdi Ghani,Jing Guo,Christine Sato,Danielle Moreno,Yan Liang,Julia Keith,Bryan J. Traynor,Peter St George-Hyslop,Peter St George-Hyslop,Ekaterina Rogaeva +26 more
TL;DR: In this paper, the authors identified a known CHD10 pathogenic p.R15L mutation in a patient with sporadic ALS (Patient 8807) who developed symptoms involving his upper limb at 54 years of age and remains alive 12 years later.